Based on the detailed analysis of the patented securitization of the American company of Royalty Pharma, this paper combs the risks existing in the financing of China’s intellectual property securitization and puts forward some suggestions to resolve the financing risks. In this paper, we propose an approach for Credit Risk+ model and analysis of the patented securitization of the American company of Royalty Pharma. This methodology puts in evidence China’s intellectual property securitization financing exists legal risk, transaction risk, credit risk, and so on. China should pay more attention to the establishment and improvement of the relevant legal system, actively explore China’s intellectual property securitization product structure. The outcomes can help to promote the stable operation of China’s intellectual property securitization.